COMPARE · Reviewed August 3, 2026
PACS vs UHS
Verdict: Side-by-side breakdown using the Bull Rankings model. PACS scored 69.4, UHS scored 70.4 — UHS leads.
Compare another set
PACS
PACS Group, Inc.
69.4
$45.29 · $7.2B
fundamentals as of
Score gap
1.0
UHS leads
UHS
Universal Health Services, Inc.
70.4
$166.06 · $10.1B
fundamentals as of
The model, pillar by pillar (0–100 each)
PACS
stronger →← stronger
UHS
60
Qualityreturns · margins · balance sheet
69
100
Growthrevenue & earnings expansion
61
56
Valuevaluation vs sector peers
83
UHS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
PACS
UHS
$151mC
FCF
$913mC+
+22.2%A-
Rev
+10.4%B
3.36D
D/E
0.69C+
29.2xB
P/E
6.8xA
1.35B
PEG
1.20B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
PACS
UHS
207% above
Price vs fair valuelower is cheaper
28% below
~33%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-3%/yr
-68%
1-yr DCF upside
+32%
-67%
5-yr DCF upside
+40%
-66%
10-yr DCF upside
+51%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
PACS
Why this score
- Diluting shareholders
- Short track record
UHS
Why this score
- Buying back stock
The companies
PACSPACS Group, Inc.
Why now
Medical Care Facilities · market cap $7.2b. 6% off the 52-week high of $48.00. Revenue growing +22%, comfortably above the S&P median. 6 sell-side analysts publish a mean 1-yr target of $52.67 (implying +16% upside).
Moat
ROE 24% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
D/E 3.36 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Net margin 4.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
UHSUniversal Health Services, Inc.
Why now
Medical Care Facilities · market cap $10.1b. Down 33% from 52-week high of $246.33 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $193.88 (implying +17% upside).
Moat
ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.